Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 567-577

  Nattel, Stanley ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Action potential duration; Cardiac arrhythmia; Early afterdepolarization; Ion channel blocker; Ischemic heart disease; Pharmacology; Potassium channel blocker; Sodium channel blocker

Indexed keywords

AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; ENCAINIDE; FLECAINIDE; ION CHANNEL; MORACIZINE; POTASSIUM CHANNEL BLOCKING AGENT; PROCAINAMIDE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL;

ACTION POTENTIAL; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DEPOLARIZATION; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; LONG QT SYNDROME; MORTALITY; PATCH CLAMP; PRIORITY JOURNAL; REVIEW; TACHYCARDIA;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; POTASSIUM CHANNEL BLOCKERS; SODIUM CHANNEL BLOCKERS;

EID: 0032029141     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00293-9     Document Type: Review

References (100)

1. [1] The Cardiac Arrhythmia Suppression Trial (CAST) Investigators, Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;3321:406-412.
2. [2] The Cardiac Arrhythmia Suppression Trial II (CAST) Investigators, Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
3. [3] IMPACT Research Group. International Mexiletine and Placebo Antiarrhythmic Coronary Trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984;4:1148-1163
4. [4] Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12. for the SWORD Investigators.
5. [5] Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
6. [6] Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532. on Behalf of the Stroke Prevention in Atrial Fibrillation Investigators.
7. [7] Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994;48:345-371.
8. [8] Moosvi AR, Goldstein S, VanderBrug Medendorp S, et al. Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease. Am J Cardiol 1990;65:1192-1197.
9. [9] Selzer A, Wray HW. Quinidine syncope - paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17-26.
10. [10] Campbell TJ. Kinetics of onset of rate-dependent effects of class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res 1983;17:344-352.
11. [11] Winkle RA, Mason JW, Griffin JC, Ross D. Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 1981;102:857-863.
12. [12] Rinkenberger RL, Prystowsky EN, Jackman WM, et al. Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms. Am Heart J 1982;103:177-184.
13. [13] Morganroth J, Horowitz LN. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984;53:89B-94B.
14. [14] Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987;59:32E-37E.
15. [15] Miyazaki T, Ogawa S, Sakai T, et al. Effects of class I drugs on reentrant ventricular tachycardia in a canine model of myocardial infarction: on their antiarrhythmic and proarrhythmic mechanisms. Jpn Circ J 1988;52:254-261.
16. [16] Sakai T, Ogawa S, Hosokawa M, et al. Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. Cardiovasc Res 1989;23:177-183.
17. [17] Steinberg JS, Sahar DI, Rosenbaum M, Cook JR, Bigger JT Jr.. Proarrhythmic effects of procainamide and tocainide in a canine infarction model. J Cardiovasc Pharmacol 1992;19:52-59.
18. [18] Kidwell GA, Gonzalez MD. Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects. J Cardiovasc Pharmacol 1993;21:621-632.
19. [19] Wallace AA, Stupienski RF III, Kothstein T, Gehret JR, Lynch JJ Jr.. Demonstration of proarrhythmic activity with the class IC antiarrhythmic agent encainide in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1993;21:397-404.
20. [20] Ranger S, Nattel S. Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation 1995;92:1300-1311.
21. [21] Restivo M, Yin H, Caref EB, et al. Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. Circulation 1995;91:1236-1246.
22. [22] Coromilas J, Saltman AE, Waldecker B, Dillon SM, Wit AL. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation 1995;91:2245-2263.
23. [23] Elharrar V, Zipes DP. Cardiac electrophysiologic alterations during myocardial ischemia. Am J Physiol 1977;233:H329-H345.
24. [24] Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-1169.
25. [25] Elharrar V, Gaum WE, Zipes DP. Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol 1977;39:544-549.
26. [26] Nattel S, Pedersen DH, Zipes DP. Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981;15:80-85.
27. [27] Carson DL, Cardinal R, Savard P, et al. Relationship between an arrhythmogenic action of lidocaine and its effects on excitation patterns in acutely ischemic porcine myocardium. J Cardiovasc Pharmacol 1986;8:126-136.
28. [28] Aupetit JF, Timour Q, Loufoua-Moundanga J, et al. Profibrillatory effects of lidocaine in the acutely ischemic porcine heart. J Cardiovasc Pharmacol 1995;25:810-816.
29. [29] Kou WH, Nelson SD, Lynch JJ, et al. Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 1987;9:359-365.
30. [30] Lederman SN, Wenger TL, Bolster DE, Strauss HC. Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. J Cardiovasc Pharmacol 1989;13:541-546.
31. [31] Hondeghem LM. Antiarrhythmic agents: modulated receptor applications. Circulation 1987;75:514-520.
32. [32] Starmer CF, Lastra AA, Nesterenko VV, Grant AO. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments. Circulation 1991;84:1364-1377.
33. [33] Starmer CF, Biktashev VN, Romashko DN, et al. Vulnerability in an excitable medium: analytical and numerical studies of initiating unidirectional propagation. Biophys J 1993;65:1775-1787.
34. [34] Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium - Phase 2 reentry?. Circulation 1993;87:562-572.
35. [35] Nattel S, Keable H, Sasyniuk BJ. Experimental amitriptyline intoxication: electrophysiologic manifestations and management. J Cardiovasc Pharmacol 1984;6:83-89.
36. [36] Nattel S. Frequency-dependent effects of amitriptyline on ventricular conduction and cardiac rhythm in dogs. Circulation 1985;72:898-906.
37. [37] Salerno DM, Murakami MAM, Asinger DA, et al. Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate vs. normal saline in dogs: a blinded randomized comparison. J Am Coll Cardiol 1991;17:43A. abstract.
38. [38] Nesterenko VV, Lastra AA, Rosenshtraukh LV, Starmer CF. A proarrhythmic response to sodium channel blockade: modulation of the vulnerable period in guinea pig ventricular myocardium. J Cardiovasc Pharmacol 1992;19:810-820.
39. [39] Brugada J, Boersma L, Kirchhof C, Allessie M. Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. Circulation 1991;84:1808-1818.
40. [40] Nattel S, Waters D. What is an antiarrhythmic drug? From clinical trials to fundamental concepts. Am J Cardiol 1990;66:96-100.
41. [41] Greenberg HM, Dwyer EM Jr., Hochman JS, et al. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995;74:631-635.
42. [42] Salerno DM, Granrud G, Sharkey P, et al. Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther 1986;40:101-107.
43. [43] Nattel S, DeBlasio E, Matthews C, Ranger S, Yue L. What is the mechanism of flecainide's proarrhythmic effect in cast?. Can J Cardiol 1994;10(Suppl. C): 131C. abstract.
44. [44] Nattel S, Tunnel N, MacLeod R, Solymoss BC. Actions of intravenous magnesium on ventricular arrhythmias caused by acute myocardial infarction. J Pharmacol Exp Ther 1991;259:939-946.
45. [45] Dessertenne F. La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 1966;59:263-272.
46. [46] Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol 1986;8:73A-78A.
47. [47] Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndrome: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172.
48. [48] Dangman KH, Hoffman BF. In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J Pharmacol Exp Ther 1981;217:851-862.
49. [49] Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 1983;68:846-856.
50. [50] Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers. Relationship to potassium and cycle length. Circ Res 1985;56:857-867.
51. [51] Nattel S, Quantz MA. Pharmacological response of quinidine induced early afterdepolarisations in canine cardiac Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc Res 1988;22:808-817.
52. [52] Davidenko JM, Cohen L, Goodrow R, Antzelevitch C. Quinidine-induced action potential prolongation, early afterdepolarizations, and triggered activity in canine Purkinje fibers. Effects of stimulation rate, potassium, and magnesium. Circulation 1989;79:674-686.
53. [53] Karagueuzian HS, Khan SS, Hong K, et al. Action potential alternants and irregular dynamics in quinidine-intoxicated ventricular muscle cells. Implications for ventricular proarrhythmia. Circulation 1993;87:1661-1672.
54. [54] Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res 1991;68:1729-1741.
55. [55] Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and Torsade de Pointes. J Am Coll Cardiol 1994;23:259-277.
56. [56] Levine JH, Spear JF, Guarnieri T, et al. Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation 1985;72:1092-1103.
57. [57] Hanich RF, Levine JH, Spear JF, Moore EN. Autonomic modulation of ventricular arrhythmia in cesium chloride-induced long QT syndrome. Circulation 1988;77:1149-1161.
58. [58] Bailie DS, Inoue H, Kaseda S, Ben-David J, Zipes DP. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation 1988;77:1395-1402.
59. [59] Nayebpour M, Nattel S. Pharmacologic response of celsium-induced ventricular tachyarrhythmias in anesthetized dogs. J Cardiovasc Pharmacol 1990;15:552-561.
60. [60] Takahashi N, Ito M, Ishida S, et al. Effects of vagal stimulation on cesium-induced early afterdepolarizations and ventricular arrhythmias in rabbits. Circulation 1992;86:1987-1992.
61. [61] El-Sherif N, Bekheit SS, Henkin R. Quinidine-induced long QTU interval and Torsade de Pointes: role of bradycardia-dependent early afterdepolarizations. J Am Coll Cardiol 1989;14:252-257.
62. [62] Nayebpour M, Solymoss BC, Nattel S. Cardiovascular and metabolic effects of caesium chloride injection in dogs - limitalions as a model for the long QT syndrome. Cardiovasc Res 1989;23:756-766.
63. [63] Weissenburger J, Davy JM, Chézalviel F, et al. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lido caine, flecainide, propranolol and sotalol. J Pharmacol Exp Ther 1991;259:871-883.
64. [64] Weissenburger J, Chezalviel F, Davy JM, et al. Methods and limitations of an experimental model of long QT syndrome. J Pharmacol Methods 1991;26:23-42.
65. [65] Vos MA, Verduyn SC, Gorgels APM, Lipcsei GC, Wellens HJJ. Reproducible induction of early afterdepolarizations and Torsade de Pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 1995;91:864-872.
66. [66] Carlsson L, Almgren O, Duker G. QTU-prolongation and Torsades de Pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990;16:276-285.
67. [67] Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Cardiovasc Res 1993;27:2186-2193.
68. [68] Verduyn SC, Vos MA, van der Zande J, van der Hulst FF, Wellens HJ. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: reversal by magnesium. Cardiovasc Res 1997;34:453-463.
69. [69] Bardy GH, Ungerleider RM, Smith WM, Ideker RE. A mechanism of Torsades de Pointes in a canine model. Circulation 1983;67:52-59.
70. [70] Inoue H, Murakawa Y, Toda I, et al. Epicardial activation patterns of Torsade de Pointes in canine hearts with quinidine-induced long QT interval but without myocardial infarction. Am Heart J 1986;111:1080-1087.
71. [71] El-Sherif N, Zeiler RH, Craelius W, Gough WB, Henkin R. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Afterdepolarizations and ventricular arrhythmias. Circ Res 1988;63:286-305.
72. [72] El-Sherif N, Caref EB, Yin H, Restivo M. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. Circ Res 1996;79:474-492.
73. [73] Asano Y, Davidenko JM, Baxter WT, Gray RA, Jalife J. Optical mapping of drug-induced polymorphic arrhythmias and Torsade de Pointes in the isolated rabbit heart. J Am Coll Cardiol 1997;29:831-842.
74. [74] Starmer CF, Romashko DN, Reddy RS, et al. Proarrhythmic response to potassium channel blockade. Numerical studies of polymorphic tachyarrhythmias. Circulation 1995;92:595-605.
75. [75] Keating MT. Genetic approaches to cardiovascular disease. Supravalvular aortic stenosis, Williams syndrome, and long-QT syndrome. Circulation 1995;92:142-147.
76. [76] Roden DM, George AL Jr., Bennett PB. Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol 1995;6:1023-1031.
77. [77] Kass RS, Davies MP. The roles of ion channels in an inherited heart disease: molecular genetics of the long QT syndrome. Cardiovasc Res 1996;32:443-454.
78. Kr potassium channel. Cell 1995;81:299-307.
79. [79] Bennett PB, Yazawa K, Makita N, George AL Jr.. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995;376:683-685.
80. + channel-linked long-QT syndrome. Circ Res 1996;78:916-924.
81. Ks cardiac potassium current. Nature 1996;384:78-80.
82. Ks potassium channel. Nature 1996;384:80-83.
83. [83] Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996;94:2572-2579.
84. [84] Roy ML, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996;94:817-823.
85. [85] Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonist terfenadine and astemizole. FEBS Lett 1996;385:77-80.
86. [86] Hohnloser SH, Meinertz T. Recorded sudden cardiac death: relationship to antiarrhythmic therapy. Eur Heart J 1988;9(Suppl. B):27-31.
87. [87] Gough WB, El-Sherif N. The differential response of normal and ischaemic Purkinje fibres to clofilium, d-sotalol and bretylium. Cardiovasc Res 1989;23:554-559.
88. [88] Bigger JT. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 1987;75(Suppl. IV):28-35.
89. [89] Thuringer D, Deroubaix E, Coulombe A, Coraboeuf E, Mercadier JJ. Ionic basis of the action potential prolongation in ventricular myocytes from Syrian hamsters with dilated cardiomyopathy. Cardiovasc Res 1996;31:747-757.
90. [90] Kääb S, Nuss HB, Chiamvimonvat N, et al. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996;78:262-273.
91. + current similar to Kv1.5 cloned channel currents. Circ Res 1993;73:1061-1076.
92. [92] Li GR, Feng J, Yue L, Carrier M, Nattel S. Evidence for two components of delayed rectifier potassium current in human ventricular myocytes. Circ Res 1996;78:689-696.
93. [93] Hondeghem LM. Computer aided development of antiarrhythmic drugs with class IIIa properties. J Cardiovasc Electrophysiol 1994;5:5711-5721.
94. [94] Snyders DJ, Knoth KM, Roberds SL, Tamkin MM. Time-, voltage-, and state-dependent block by quidinine of a cloned human cardiac potassium channel. Mol Pharmacol 1992;41:322-330.
95. [95] Duan D, Fermini B, Nattel S. Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 1993;264:1113-1123.
96. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-868.
97. [97] Jurkiewicz NK, Sanguinetti MC. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Circ Res 1993;72:75-83.
98. [98] Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994;90:2032-2040.
99. Ks) in human and guina pig ventricle. J Am Coll Cardiol 1997;29(suppl. A):512A. abstract.
100. [100] Fermini B, Jurkiewicz NK, Jow B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995;26:259-271.